Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 783 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bioequivalence Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Fasting Conditions

NCT00865423
View directory record Official record
Conditions
Healthy
Interventions
Gabapentin 800 mg Tablets, single dose, NEURONTIN® 800 mg Tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

NCT00902187
View directory record Official record
Conditions
Treatment of Overactive Bladder
Interventions
Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 22, 2026, 4:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects

NCT01142063
View directory record Official record
Conditions
Healthy
Interventions
Neratinib
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

NCT01099709
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 50 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated May 6, 2010 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg

NCT00647816
View directory record Official record
Conditions
Healthy
Interventions
Propranolol Hydrochloride Extended-Release Capsules 160 mg, Inderal® LA Capsules 160 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects

NCT02572245
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06410293 PFS, PF-06410293 PFP
Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg

NCT00649675
View directory record Official record
Conditions
Healthy
Interventions
Meloxicam Tablets 15 mg, Mobic® Tablets 15 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions

NCT00990301
View directory record Official record
Conditions
Healthy
Interventions
Moexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc., Uniretic® 15mg/25mg Tablets
Drug
Lead sponsor
Paddock Laboratories, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

NCT02660736
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide Liquid Auto-injector, Albiglutide Lyophilized DCC Pen Injector, Placebo Liquid Auto-injector, Placebo Lyophilized DCC Pen injector
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2016 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg

NCT00648466
View directory record Official record
Conditions
Healthy
Interventions
Sumatriptan Succinate Tablets 100 mg, Imitrex® Tablets 100 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg

NCT00649662
View directory record Official record
Conditions
Healthy
Interventions
Ciprofloxacin Extended-Release Tablets 1000 mg, Cipro® XR Tablets 1000 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers

NCT02259179
View directory record Official record
Conditions
Healthy
Interventions
Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets), Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg

NCT00650169
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel Bisulfate Tablets 75 mg, Plavix® Tablets 75 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Modafinil Tablets 200 mg and Provigil® Tablets 200 mg

NCT00650000
View directory record Official record
Conditions
Healthy
Interventions
Modafinil Tablets 200 mg, Provigil® Tablets 200 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets

NCT00853736
View directory record Official record
Conditions
Healthy
Interventions
Roxicodone™ tablet 30 mg, Oxycodone hydrochloride tablet 30 mg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasting Conditions

NCT00864617
View directory record Official record
Conditions
Healthy
Interventions
Nifedipine Extended Release tablets 60 mg, single dose, ADALAT® CC Extended Release Tablets 60 mg
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg

NCT01184391
View directory record Official record
Conditions
Healthy
Interventions
DEPAKOTE® Tablets, 500 MG, DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Metformin Hydrochloride ER Tablets 750 mg and Glucophage® XR Tablets 750 mg

NCT00648518
View directory record Official record
Conditions
Healthy
Interventions
Metformin Hydrochloride ER Tablets 750 mg, Glucophage® XR Tablets 750 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face

NCT02800148
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic acid foam, Azelaic acid foam - Placebo
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional

A Study Comparing Oxymetazoline 1% Cream to RHOFADE

NCT05148689
View directory record Official record
Conditions
Bioequivalence
Interventions
Oxymetazoline hydrochloride Cream, 1%, Rhofade™ (oxymetazoline) cream, 1%, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions

NCT01903122
View directory record Official record
Conditions
Dry Mouth
Interventions
Cevimeline
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone

NCT07046975
View directory record Official record
Conditions
Bioavailability Heathy Volunteers
Interventions
Torsemide and Spironolactone tablet, Torsemide Tablets and Spironolactone Tablets
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Results available

Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule

NCT03329001
View directory record Official record
Conditions
Neoplasms
Interventions
Niraparib Tablet, Niraparib Capsule
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
16
States / cities
Encinitas, California • Fresno, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

NCT02741557
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
DTG, RPV, DTG/RPV FDC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 22, 2026, 4:59 AM EDT